Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
1.06
USD
|
-5.36%
|
|
+17.80%
|
-23.19%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5,426
|
4,855
|
2,872
|
700.4
|
573.7
|
204.3
|
204.3
|
-
|
Enterprise Value (EV)
1 |
4,194
|
3,749
|
1,721
|
400.9
|
393.4
|
-36.49
|
98.3
|
140.4
|
P/E ratio
|
-9.29
x
|
-6.13
x
|
-4.35
x
|
-0.84
x
|
-2.04
x
|
-0.64
x
|
-0.68
x
|
-1.17
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
99.4
x
|
109
x
|
11.5
x
|
191
x
|
160
x
|
5.47
x
|
1.65
x
|
0.8
x
|
EV / Revenue
|
76.8
x
|
83.9
x
|
6.86
x
|
109
x
|
109
x
|
-0.98
x
|
0.8
x
|
0.55
x
|
EV / EBITDA
|
-7.56
x
|
-4.7
x
|
-2.85
x
|
-0.7
x
|
-1.04
x
|
0.14
x
|
-0.43
x
|
-0.98
x
|
EV / FCF
|
-8.94
x
|
-5.9
x
|
-3.45
x
|
-0.62
x
|
-
|
0.11
x
|
-0.3
x
|
-0.6
x
|
FCF Yield
|
-11.2%
|
-16.9%
|
-29%
|
-162%
|
-
|
896%
|
-329%
|
-167%
|
Price to Book
|
2.88
x
|
3.78
x
|
2.12
x
|
1.9
x
|
2.92
x
|
0.52
x
|
1.44
x
|
1.68
x
|
Nbr of stocks (in thousands)
|
54,694
|
55,331
|
66,373
|
70,107
|
82,910
|
192,742
|
192,742
|
-
|
Reference price
2 |
99.20
|
87.75
|
43.27
|
9.990
|
6.920
|
1.060
|
1.060
|
1.060
|
Announcement Date
|
2/21/19
|
2/18/20
|
2/23/21
|
3/4/22
|
3/29/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
54.58
|
44.67
|
250.7
|
3.662
|
3.597
|
37.38
|
123.5
|
256.6
|
EBITDA
1 |
-554.9
|
-797.4
|
-603.7
|
-571.3
|
-379.2
|
-266.4
|
-230.2
|
-142.6
|
EBIT
1 |
-572
|
-814.8
|
-623
|
-590.9
|
-384.2
|
-276.9
|
-261.2
|
-192.3
|
Operating Margin
|
-1,048.06%
|
-1,823.94%
|
-248.49%
|
-16,136.29%
|
-10,679.79%
|
-740.8%
|
-211.49%
|
-74.91%
|
Earnings before Tax (EBT)
1 |
-555.4
|
-790.2
|
-618
|
-562.4
|
-266.5
|
-198.8
|
-246.3
|
-179.6
|
Net income
1 |
-555.6
|
-789.6
|
-618.7
|
-819.4
|
-266.6
|
-199.1
|
-238.2
|
-171.9
|
Net margin
|
-1,018.02%
|
-1,767.49%
|
-246.75%
|
-22,375.15%
|
-7,411.12%
|
-532.47%
|
-192.86%
|
-66.99%
|
EPS
2 |
-10.68
|
-14.31
|
-9.950
|
-11.89
|
-3.390
|
-1.664
|
-1.568
|
-0.9046
|
Free Cash Flow
1 |
-469.2
|
-635.4
|
-499.3
|
-650.1
|
-
|
-327
|
-323
|
-235
|
FCF margin
|
-859.6%
|
-1,422.33%
|
-199.15%
|
-17,753.74%
|
-
|
-874.74%
|
-261.54%
|
-91.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/21/19
|
2/18/20
|
2/23/21
|
3/4/22
|
3/29/23
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
7.472
|
22.68
|
1.606
|
1.945
|
1.519
|
0.071
|
0.062
|
2.381
|
6.89
|
12.39
|
13.88
|
17.11
|
22.75
|
30.02
|
50.65
|
EBITDA
1 |
-234.8
|
-190.8
|
-133.4
|
-119.3
|
-99.42
|
-85.09
|
-75.31
|
-83.41
|
-84.33
|
-83.66
|
-102.3
|
-
|
-
|
-
|
-
|
EBIT
1 |
-240.8
|
-196.8
|
-135.7
|
-120.3
|
-100.8
|
-86.48
|
-76.56
|
-84.49
|
-85.3
|
-84.73
|
-87.56
|
-76.44
|
-71.82
|
-66.87
|
-53.58
|
Operating Margin
|
-3,223.21%
|
-867.75%
|
-8,447.51%
|
-6,187.46%
|
-6,633.38%
|
-121,802.82%
|
-123,491.94%
|
-3,548.64%
|
-1,237.98%
|
-683.74%
|
-630.69%
|
-446.83%
|
-315.67%
|
-222.75%
|
-105.78%
|
Earnings before Tax (EBT)
1 |
-241.5
|
-216.9
|
-132.2
|
-122.2
|
-100.1
|
-76.51
|
32.34
|
21.24
|
-72.99
|
-71.73
|
-78.41
|
-70.07
|
-66.45
|
-59.97
|
-46.84
|
Net income
1 |
-241.7
|
-216.8
|
-155.1
|
-122.2
|
-100.1
|
-76.52
|
32.23
|
21.24
|
-72.91
|
-71.73
|
-82.49
|
-67.9
|
-65.86
|
-59.19
|
-45.14
|
Net margin
|
-3,234.77%
|
-956.11%
|
-9,654.55%
|
-6,280.31%
|
-6,592.36%
|
-107,774.65%
|
51,987.1%
|
892.06%
|
-1,058.17%
|
-578.85%
|
-594.19%
|
-396.88%
|
-289.44%
|
-197.18%
|
-89.12%
|
EPS
2 |
-3.580
|
-3.160
|
-2.140
|
-1.660
|
-1.360
|
-0.9400
|
0.3800
|
0.2100
|
-0.6700
|
-0.6600
|
-0.6281
|
-0.4150
|
-0.4025
|
-0.3550
|
-0.2829
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/9/21
|
11/5/21
|
3/4/22
|
5/9/22
|
8/4/22
|
11/7/22
|
3/29/23
|
5/9/23
|
8/8/23
|
11/7/23
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,232
|
1,106
|
1,151
|
300
|
180
|
241
|
106
|
63.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-469
|
-635
|
-499
|
-650
|
-
|
-327
|
-323
|
-235
|
ROE (net income / shareholders' equity)
|
-31.7%
|
-49.8%
|
-46.9%
|
-94.8%
|
-93.4%
|
-105%
|
-122%
|
-113%
|
ROA (Net income/ Total Assets)
|
-26.8%
|
-39.8%
|
-35.3%
|
-69%
|
-
|
-40.5%
|
-80.2%
|
-88.1%
|
Assets
1 |
2,072
|
1,985
|
1,754
|
1,188
|
-
|
491.5
|
297
|
195.2
|
Book Value Per Share
2 |
34.40
|
23.20
|
20.40
|
5.260
|
2.370
|
2.040
|
0.7300
|
0.6300
|
Cash Flow per Share
2 |
-7.950
|
-10.20
|
-7.560
|
-9.220
|
-4.490
|
-1.720
|
-1.130
|
-0.7400
|
Capex
1 |
55.7
|
71
|
29
|
14.5
|
8.21
|
6.99
|
6.56
|
6.52
|
Capex / Sales
|
102.12%
|
158.99%
|
11.56%
|
396.04%
|
228.19%
|
18.7%
|
5.31%
|
2.54%
|
Announcement Date
|
2/21/19
|
2/18/20
|
2/23/21
|
3/4/22
|
3/29/23
|
-
|
-
|
-
|
Last Close Price
1.06
USD Average target price
4.062
USD Spread / Average Target +283.18% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.19% | 204M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|